Bevacizumab in Combination with Modified FOLFOX6 in Heavily Pretreated Patients with HER2/Neu-Negative Metastatic Breast Cancer: A Phase II Clinical Trial. - Wikidata - wikimedia - TriplyDB

Bevacizumab in Combination with Modified FOLFOX6 in Heavily Pretreated Patients with HER2/Neu-Negative Metastatic Breast Cancer: A Phase II Clinical Trial.

Bevacizumab in Combination with Modified FOLFOX6 in Heavily Pretreated Patients with HER2/Neu-Negative Metastatic Breast Cancer: A Phase II Clinical Trial.

http://www.wikidata.org/entity/Q33424566

about

Apatinib for metastatic breast cancer in non-clinical trial setting: Satisfying efficacy regardless of previous anti-angiogenic treatment.Analysis of the activity and safety of weekly low-dose bevacizumab-based regimens in heavily pretreated patients with metastatic breast cancer.

P2860

Q47339196-B7C90945-097B-4933-92C2-B1F8C5324060 Q55286810-968D842F-B32B-429D-867B-D44CC4C5174A

P2860

Bevacizumab in Combination with Modified FOLFOX6 in Heavily Pretreated Patients with HER2/Neu-Negative Metastatic Breast Cancer: A Phase II Clinical Trial.

http://www.wikidata.org/entity/Q33424566

description

2015 nî lūn-bûn

@nan

2015 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Bevacizumab in Combination wit ...... er: A Phase II Clinical Trial.

@ast

Bevacizumab in Combination wit ...... er: A Phase II Clinical Trial.

@en

type

label

Bevacizumab in Combination wit ...... er: A Phase II Clinical Trial.

@ast

Bevacizumab in Combination wit ...... er: A Phase II Clinical Trial.

@en

prefLabel

Bevacizumab in Combination wit ...... er: A Phase II Clinical Trial.

@ast

Bevacizumab in Combination wit ...... er: A Phase II Clinical Trial.

@en

P1433

Q33424566-DE964B7E-F657-42D9-98CC-31AE23118734

P1476

Q33424566-8FDCDEF2-B8E6-4D81-AD02-EC4146661D0F

P2093

Q33424566-0E3FEB73-4AC6-4646-866C-546E0692B3D7

Q33424566-43419A9F-367A-4B58-8C36-E832CD5804C3

Q33424566-51A33563-73ED-40B7-A56D-8BE46C310B93

Q33424566-53BF607C-4CC4-413A-9DD6-AFD02490F37F

Q33424566-6429A160-D79F-4930-BA5B-399963809160

Q33424566-6F8CB666-55EF-4CC6-9640-D9046905EABE

Q33424566-6F9681A2-EC80-4F91-A84B-E8E66C2AF163

Q33424566-87BC9141-9F74-4FEC-A658-0E2D49E4DD18

Q33424566-93A21714-A583-4F64-9722-9DA68F43383D

Q33424566-9E83BD4A-1055-4263-9A10-CF1BDE258DEA

P2860

Q33424566-082AF106-A2EB-4596-A357-8FA76D9D2111

Q33424566-0D967D2B-9B8A-44A4-B38A-EAF2C86A6BA6

Q33424566-145A6786-40F3-4ABE-B633-AC73AA8E562A

Q33424566-162A5CEF-7DE8-4FB5-80AB-F84550DA923D

Q33424566-1D3E256A-B10A-4DC2-88D0-CF72B23D8072

Q33424566-1DF76C55-6887-4C76-955A-F507AF2A302A

Q33424566-2769142D-0FDB-4E1C-AA6C-3BE7D9F8ED47

Q33424566-2F5004B9-DC9F-40EE-9718-3F42B758B3AB

Q33424566-2F515E0A-C3DB-4DAB-855C-B9AEE861E6FE

Q33424566-31BF4D82-48C2-4E92-90D6-F87AFD7E4BCB

P304

Q33424566-4DAFF5B3-C039-4E5F-B90D-4C2123323CBA

P31

Q33424566-DE625FD0-480E-46B5-A1C1-3E3DA2222909

P356

Q33424566-935040E3-0609-44F6-9FCB-A6DF7C9C61A7

P407

Q33424566-67CD2325-97E6-4276-8AB6-6B90B387686A

P433

Q33424566-2EE1264B-BE88-413F-B15A-AAA6C0622D71

P478

Q33424566-567E524B-6E26-47C8-830C-445A0C3C972B

P577

Q33424566-C7023093-B9CB-4ED9-89B9-62A62405664F

P5875

Q33424566-3AFA1C1E-1AD5-4353-B7AE-F32877D66285

P698

Q33424566-44637410-6228-4522-9211-BB1159E1DEFB

P921

Q33424566-189F7ED8-EE31-47A7-8E71-6429612A6806

Q33424566-777FB121-D2F9-464B-9C3D-0DD7EB93B8A1

P932

Q33424566-DD4ED9A0-89AA-4475-B4EF-B401374325B2

P356

JOURNAL.PONE.0133133

P1433

P1476

Bevacizumab in Combination wit ...... er: A Phase II Clinical Trial.

@en

P2093

Biyun Wang

http://www.w3.org/2001/XMLSchema#string

Chen Ni

http://www.w3.org/2001/XMLSchema#string

Fangfang Lv

http://www.w3.org/2001/XMLSchema#string

Jian Zhang

http://www.w3.org/2001/XMLSchema#string

Jie Xie

http://www.w3.org/2001/XMLSchema#string

Joseph Ragaz

http://www.w3.org/2001/XMLSchema#string

Jun Cao

http://www.w3.org/2001/XMLSchema#string

Leiping Wang

http://www.w3.org/2001/XMLSchema#string

Sheng Zhang

http://www.w3.org/2001/XMLSchema#string

Si Sun

http://www.w3.org/2001/XMLSchema#string

P2860

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

Toxicity and response criteria of the Eastern Cooperative Oncology Group

Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).

Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial

An updated meta-analysis of fatal adverse events caused by bevacizumab therapy in cancer patients.

Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane.

Phase II study of oxaliplatin and fluorouracil in taxane- and anthracycline-pretreated breast cancer patients.

Oxaliplatin plus high-dose leucovorin and 5-fluorouracil in pretreated advanced breast cancer: a phase II study.

Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer.

P304

e0133133

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0133133

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2015-07-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

281822071

http://www.w3.org/2001/XMLSchema#string

P698

26186012

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

4506015

http://www.w3.org/2001/XMLSchema#string